Effectiveness of short-term 6-hour high-volume hemofiltration during refractory severe septic shock.
BACKGROUND
The effectiveness of a single 6-hour session of high-volume hemofiltration (HVHF) was evaluated in terms of decreased norepinephrine (NE) requirements, progressive refractory hypotension and hypoperfusion by the fourth hour, and observed versus expected hospital mortality in patients with refractory severe septic shock.


METHODS
A prospective cohort study conducted at the intensive care unit with 31 patients suffering from severe septic shock (NE dose ≥ 0.3 μg kg min to maintain mean arterial pressure 70-80 mm Hg and lactic acidosis) and refractory to treatments recommended by Surviving Sepsis Campaign, 2008. All patients were subjected to a single short-term 6-hour HVHF with a goal-directed protocol. Changes in NE dose, hemodynamic, metabolic, and respiratory parameters were measured at the onset (t0), 4 (t4) and 6 hours (t6) during HVHF. Patients were considered responders if by t4 of HVHF, they showed a decrease in NE dose ≥ 50%, maintaining mean arterial pressure 80 mm Hg to 70 mm Hg.


RESULTS
: Twenty-five of the 31 patients responded to HVHF treatment (responders), whereas 6 did not (nonresponders). In the responders group, a decrease in NE dose was observed by t4 (1.3 ± 0.5 μg kg min). This beneficial effect was maintained by t6 of treatment. Hemodynamic, metabolic, and respiratory parameters and other organic function indicators were also significantly improved by t4 and maintained by t6. Hospital mortality (45.16%) was significantly lower than that predicted by Sequential Organ Failure Assessment score (>90%): 83% for nonresponders versus 36% for responders.


CONCLUSIONS
We conclude that a single session of short-term 6-hour HVHF in patients with refractory severe septic shock reduces NE dose requirements and improves organic function already by the fourth hour of treatment.


METHODS
III, therapeutic study.
Universidad Católica de Chile, Unidad de Cuidados Intensivos, Marcoleta 367, 8330024 Santiago, Chile. pstapia@uc.cl
Pablo
P
Tapia
Eduardo
E
Chinchón
Danny
D
Morales
Jimmy
J
Stehberg
Felipe
F
Simon
D002677:Chile / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000502:physiology*; D006440:Hemofiltration / Q000379:methods*; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012129:Respiratory Function Tests; D012772:Shock, Septic / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome